tcl1a  (Novus Biologicals)

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: A strong correlation between TCL1A and AML was identified by Mendelian randomization. A Forest plot of the top five plasma proteins most associated with AML. Scatter plots of B ADGRF5, C FLRT2, D GRAP2, E PPIC, and F TCL1A with AML. G Volcano plot showing the relationship between plasma proteins and AML. Note: AML: acute myelogenous leukemia

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques: Clinical Proteomics

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: TCL1A-eqTL showed a significant positive association with AML by Mendelian randomization. A Chromosomal localization of TCL1A. B Forest plot, C scatter plots, D leave-one-out plot, and E funnel plots of TCL1A-eqTL and AML. F Bayesian co-localization analysis between TCL1A-eqTL and AML. Note: AML: acute myelogenous leukemia

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques:

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: Expression differences of TCL1A. A ROC curves for TCL1A. B Differences in TCL1A expression between AML patients and healthy donors, and differences in TCL1A expression in subgroups by C , D age, E sex, F WBC count, G BM blast percentage, H PB blast percentage, I Cytogenetic risk, J FAB classifications, K Cytogenetics, L FLT3 mutation, M RAS mutation, N IDH1 R132 mutation, and O NPM1 mutation. Note: AML: acute myelogenous leukemia; WBC: white blood cell; BM: bone marrow; PB: peripheral blood. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques: Expressing, Mutagenesis

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: High TCL1A expression was linked to poor prognosis in AML patients through bioinformatics analysis. A KM analysis of AML patients and subgroups by karyotype: B good, C intermediate, D poor; FAB classification: E M0, F M1, G M2, H M3, I M4, J M5, G M6; L untreated and M chemotherapy stratified; and molecular risk classification: N IDH1 mutation, O IDH2 mutation, P NPM1 mutation, Q , R FLT3 mutation, S NRAS mutation, T CEBPA mutation. Note: AML: acute myelogenous leukemia; KM analysis: Kaplan–Meier analysis; FAB: French-American-British classification

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques: Expressing, Molecular Risk, Mutagenesis

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: The expression of TCL1A is highly specific in tissues and cell lines. A The mutational landscape of TCL1A in the genome of AML. Distribution of TCL1A expression in B tissues and C cell lines. D The IHC results of TCL1A in different tumor types, showing its subcellular localization. Note: AML: acute myelogenous leukemia; IHC: immunohistochemistry

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques: Expressing, Immunohistochemistry

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: Potential therapeutic agents for TCL1A identified through virtual screening. A Potential therapeutic agents for TCL1A were screened using HTVS and B sorted according to docking scores. ( C ) Compounds satisfying all three criteria. Note: HTVS: high-throughput virtual screening

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques: High Throughput Screening Assay

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: Molecular docking shows high binding affinity between small molecule compounds and TCL1A. Prediction and visualization of the interaction force between A 0449–0045, B N060-0154, C 2292159–89–6, D N025-0034, E N025-0034, F 0120–0021, G 0827–0413, H 8002–5894, I 3731–0092, J 8020–8702, and TCL1A, respectively

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques: Binding Assay

Journal: BMC Cancer

Article Title: New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

doi: 10.1186/s12885-025-15438-5

Figure Lengend Snippet: Specific expression of TCL1A in leukemia cells and the potential therapeutic effect of Bletilloside A. A The expression levels of TCL1A mRNA in AML cells, normal bone marrow stromal cells, and other solid cancer cells. ( B RMSD, C Rg, D SASA, E HBonds, and F RMSF value of Bletilloside A-TCL1A complexes over time. Note: Normal bone marrow stromal cells are shown as black labels, AML cells as red labels, and solid tumor cells as blue labels; RMSD: root mean square deviation; RMSF: root mean square fluctuation; HBonds: hydrogen bonds; Rg: radius of gyration; SASA: solvent accessible surface area

Article Snippet: The membranes were incubated overnight with primary antibodies against TCL1A (Proteintech, #10,475–1-AP), β-actin (Cell Signaling Technology (CST), #4970).

Techniques: Expressing, Solvent